Publications by authors named "Lisa H Buckley"
Patient-reported outcomes are based on patient (or caregiver) descriptions without direct measurement by a health care provider. To capture patient-reported outcomes, various patient-reported outcome measures (PROMs) have been created. Using PROMs has been linked to improved patient satisfaction, patient-provider communication, and clinical outcomes in many pediatric fields.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess how tumor necrosis factor inhibitor (TNFi) therapies and the use of conventional synthetic disease-modifying antirheumatic drugs (DMARDs) affect the occurrence of psoriasis in children with conditions like inflammatory bowel disease (IBD), juvenile idiopathic arthritis (JIA), and chronic nonbacterial osteomyelitis (CNO).
- Conducted from 2008 to 2020, the research involved 5088 children and analyzed the incidence rates of psoriasis related to TNFi and DMARD use, utilizing Poisson regression to compute incidence rate ratios.
- Results showed that children exposed to adalimumab (ADA) had the highest incidence rate of developing psoriasis, while those on TNFi
The success of rare disease research relies heavily on robust partnerships with clinicians to help identify new patients and collect samples. Many studies for paediatric rheumatic diseases requiring pretreatment samples have suffered from slow enrolment rates due to the low incidence of disease and relative urgency to treat. Therefore, timely identification of all potentially eligible patients is crucial.
View Article and Find Full Text PDFPsoriasis Associated With Tumor Necrosis Factor Inhibitors in Children With Inflammatory Diseases.
Arthritis Care Res (Hoboken)
February 2021
Objective: To estimate the incidence rate (IR) of psoriasis in children with inflammatory bowel disease (IBD), juvenile idiopathic arthritis (JIA), and chronic noninfectious osteomyelitis (CNO) with tumor necrosis factor inhibitor (TNFi) exposure as compared to children without TNFi exposure and to the general pediatric population.
Methods: This was a single-center retrospective cohort study of children with IBD, JIA, or CNO from 2008 to 2018. TNFi exposure was defined as a prescription for adalimumab, etanercept, infliximab, certolizumab, or golimumab, and the primary outcome was incident psoriasis.